BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade? As the landscape of multiple myeloma (MM) treatment evolves, two major players, Bristol-Myers Squibb (BMS) and Janssen Pharmaceutical, are vying for dominance in the burgeoning Multiple Myeloma Treatment Market. Both companies have made significant strides in advancing treatments for relapsed/refractory multiple myeloma (R/R MM), yet their approaches and pipelines differ markedly. For More https://www.delveinsight.com/blog/bms-and-janssen-multiple-myeloma-treatment-drugs